Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10508	L-Glutamic acid monosodium salt
BP10508	L-Glutamic acid monosodium salt (Monosodium glutamate) is an activator of mGlu1 receptor.
BP10654	Licofelone
BP10654	Licofelone is a dual COX/LOX inhibitor potentially for the treatment of osteoarthritis. Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-LOX may reduce the gastrointestinal toxicity associated with other non-steroidal anti-inflammatory drugs, which only inhibit COX (cyclooxygenase).
BP10747	Lificiguat
BP10747	YC-1 is an nitric oxide (NO)-independent activator of soluble guanylyl cyclase(sGC) and an inhibitor of Hypoxia-inducible factor-1alpha (HIF-1alpha).
BP10544	Lifirafenib
BP10544	Lifirafenib is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
BP10921	Liguiritigenin-7-O-D-apiosyl-4'-O-D-glucoside
BP10921	Liguiritigenin-7-O-D-Apiosyl-4'-O-D-Glucoside has antioxidant property by inducing glutathione (GSH) biosynthesis via the inhibition of cytokines and protected lung epithelial cells against cigarette smoke-mediated oxidative stress, might be as protective agent against epithelial injury in COPD.
BP10147	Ligustrazine
BP10147	Tetramethylpyrazine (ligustrazine, TMP), a natural compound isolated from Chinese herbal medicine Ligusticum wallichii (Chuan Xiong) shows anti-inflammation, antioxidant, antiplatelet, and antiapoptosis activities.
BP10202	Limonin
BP10202	Limonin is a triterpenoid enriched in citrus fruits, which has antivirus and antitumor ability.
BP10840	Loganin
BP10840	Loganin, an iridoid glucoside, has been reported to be an inhibitor of Cox-1 and also noted to suppress TNF-α formation. This compound also has displayed potent free-radical-scavenging activity and inhibitory effects on melanogenesis.
BP10562	Lorlatinib
BP10562	PF-06463922 is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.
BP10906	LQZ-7I
BP10906	LQZ-7I is an inhibitor of surviving-targeting. It orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors
BP10279	LRRK2-IN-1
BP10279	LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.
BP10090	Lucitanib
BP10090	Lucitanib is a novel VEGFR and FGFR inhibitor. It potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 (IC50s: 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively).
BP10680	Lupeol acetate
BP10680	Lupeol acetate possesses antinociceptive, antifertility, and anti-inflammatory properties, the effect probably involves the opioid system, as indicated by the complete blockade of the opioid antagonist naloxone.
BP10078	Lupiwighteone
BP10078	Lupiwighteone has anti-angiogenesis potential, it also has anticancer and cancer preventive effects on SH-SY5Y cells.
BP10640	LY 303511
BP10640	LY303511, an inactive analogue of LY294002, is a mTOR inhibitor and no inhibition for PI3-K.
BP10958	LY 303511 hydrochloride
BP10958	LY303511 (NV-128)is a potent mTOR inhibitor
BP10682	LY2857785
BP10682	LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7/CDK8/CDK9 (IC50s: 246 nM/16 nM/11 nM).
BP10296	LY2874455
BP10296	LY2874455 has been used in trials studying the treatment of Advanced Cancer.
BP10639	LY294002
BP10639	LY294002 is an inhibitor of PI3K (IC50s: 0.5/0.57/0.97 μM for PI3Kα/δ/β in cell-free assays). It also blocks autophagosome formation.
BP10985	LY-411575
BP10985	LY411575, a potent γ-secretase inhibitor, is with IC50 of 0.078 nM in the membrane and 0.082 nM in cell-based. It also suppresses Notch clevage with IC50 of 0.39 nM.